Ab&B Bio-Tech CO., LTD. JS (02627.HK)

Ab&B Bio-Tech Co., Ltd. engages in the research, development, manufacturing and commercialization of innovative and traditional vaccines. The company is headquartered in Taizhou, Jiangsu and currently employs 583 full-time employees. The company went IPO on 2025-08-08. Its product pipeline includes two core products, the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with 11 other vaccine candidates. The firm primarily operates within the domestic market.